Biocon Q4 FY26 Results Preview: Revenue, PAT Estimates

What investors are watching ahead of Q4 FY26

Biocon (NSE: BIOCON) is set to report its fourth quarter FY26 results for the period ended March 31, 2026. The company’s board is expected to meet in May 2026 to approve the audited financial statements. The same meeting is expected to consider a recommendation for a final dividend for FY26, subject to shareholder approval. With the stock at a current market price (CMP) of Rs 325 in early April 2026, the coming update is important for investors assessing the pace of improvement in earnings.

The Q4 print matters because it will shape the closing numbers for FY26 and set the base for FY27 expectations. Analysts are focused on whether operating leverage improves after recent quarterly fluctuations. The discussion on margins and capital allocation is also likely to be closely tracked given the expected dividend consideration.

Stock context: price, 52-week range, and market cap

Biocon was trading at Rs 325, down from a 52-week high of Rs 430 and above a 52-week low of Rs 280. The stock’s 1-year return was -18% as per the provided data. Market capitalisation was cited at around Rs 39,000 crore in one section, while another reference placed it at Rs 44,314.15 crore, indicating different snapshots across sources.

This price context is relevant because brokerage target prices and result expectations are being evaluated against a stock that has underperformed over the past year. Any deviation from the projected range for revenue, profitability, or margins could influence near-term sentiment.

Q4 FY26: consensus expectations on revenue, PAT, and EBITDA

Brokerage previews referenced a revenue band of Rs 4,000-4,300 crore for Q4 FY26. Profit after tax (PAT) is estimated at Rs 180-240 crore, with projected EBITDA margins of 24-27%. A key operating assumption highlighted is biosimilars growth in the US and Europe in the 15-20% range.

Q4 is often described as a seasonally important quarter as companies work toward year-end targets and dividend recommendations are made. For Biocon, the Q4 numbers are being watched against Q3 FY26 reported revenue of Rs 3,778 crore, PAT of Rs 141 crore, and EBITDA margin of 24.8%.

Recent quarterly track record: Q1 to Q3 FY26

Biocon’s Q3 FY26 revenue was also referenced in another format as INR41.7 billion, which is Rs 4,170 crore after converting to a single unit. That note said revenue grew 9.2% year-on-year (YoY) but was below an estimate of INR45.4 billion (Rs 4,540 crore). It also stated that biosimilars, which formed 58.5% of sales, rose 9.4% YoY to INR25 billion (Rs 2,500 crore).

For Q2 FY26, operating revenue was reported at Rs 4,296 crore, with net profit at Rs 85 crore. Another section described Q2 as a turnaround from losses, with revenue and EBITDA growing 20% YoY and EBITDA margin at 19%. Q2 growth was attributed to biosimilars and generics, with mentions of product launches such as bUstekinumab, bAspart, bBevacizumab, bAflibercept, and the launch of generic liraglutide.

For Q1 FY26, operating revenue was Rs 3,942 crore, up 15% YoY. Core EBITDA was Rs 1,003 crore, while EBITDA (as reported in the same release) was Rs 829 crore, up 19%, with an EBITDA margin of 21% on a like-for-like basis. Reported net profit for the quarter stood at Rs 31 crore. Segment numbers cited included biosimilars revenue of Rs 2,458 crore (up 18% YoY) and generics revenue of Rs 697 crore (up 6% YoY).

What Q4 FY25 indicates about business drivers

Biocon’s Q4 FY25 results provide a reference point for segment momentum and margin commentary. Consolidated total revenue for Q4 FY25 was Rs 4,454 crore, up 12% YoY and 15% sequentially. EBITDA for Q4 FY25 was Rs 1,115 crore, up 16%. Net profit for the quarter was Rs 344 crore, up 153%.

Biocon also reported biosimilars revenue from operations at Rs 2,463 crore in Q4 FY25, up 9% YoY, with biosimilars EBITDA at Rs 540 crore and an EBITDA margin of 22%. Full-year FY25 consolidated total revenue was Rs 16,470 crore, EBITDA was Rs 4,374 crore, and net profit was Rs 1,013 crore.

Dividend and board agenda in May 2026

The board meeting expected in May 2026 is scheduled to consider audited Q4 FY26 financial statements and a recommendation for a final dividend for FY26. One preview table also cited an expected dividend of Rs 0.5 per share. Investors typically interpret dividend decisions alongside commentary on cash flows and balance sheet priorities.

Separately, Biocon’s FY25 corporate highlights included an approval to raise funds up to Rs 4,500 crore via securities issuance through routes such as qualified institutional placements or rights issues. The stated purpose included prepayment or repayment and settlement obligations, which is relevant context when evaluating capital allocation.

Brokerage views: targets span Buy to Sell

Multiple reports in the provided text carried differing target prices and ratings. Motilal Oswal cited a Buy call with targets including Rs 460, Rs 400, and also Rs 480 in separate references. JM Financial targets cited included Rs 476 and Rs 424, along with commentary on quarterly misses versus estimates in some periods. Axis Securities was cited with a Buy and a target of Rs 450. Goldman Sachs was cited with a Neutral and target of Rs 375.

There were also references to ICICI Securities with a Sell call and target of Rs 320, and another ICICI Direct reference stating “Hold Biocon” with a target price of Rs 380. These differences underline that while earnings improvement is being tracked, conviction on near-term upside varies across brokerages.

Key numbers at a glance

Analyst targets and ratings referenced

Why the Q4 FY26 print could shift FY27 expectations

The Q4 FY26 result is positioned as a baseline for FY27 estimates in the provided preview. Investors are likely to compare sequential movement from Q3 FY26 revenue of Rs 3,778 crore to the Q4 estimate band of Rs 4,000-4,300 crore. The PAT range of Rs 180-240 crore, if achieved, would represent an improvement over Q3 FY26 PAT of Rs 141 crore.

Management’s margin commentary could be a key swing factor, given the projected EBITDA margin band of 24-27% and Q3 FY26’s EBITDA margin of 24.8%. Updates around biosimilars traction in the US and Europe, which was projected at 15-20% growth, will also be important to track because biosimilars are cited as a leading contributor to sales.

Conclusion

Biocon’s Q4 FY26 results, expected in May 2026, are in focus as brokerages model revenue of Rs 4,000-4,300 crore, PAT of Rs 180-240 crore, and EBITDA margin of 24-27%. With the stock at Rs 325 and a wide spread of targets and ratings across brokerages, the audited numbers and any board decision on the FY26 final dividend will be key near-term checkpoints.